Transcode Therapeutics, Inc. - 8-K Filing

TransCode Therapeutics initiates formal strategic process to evaluate oncology portfolio and lead candidate TTX-MC138. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $RNAZ

Read the full article at SEC EDGAR

More Regulatory news